Verified email-pattern data for Tiximed is currently limited. You can still use the company insights and contact sections below.
TIXiMED, Inc. is focused on developing and commercializing TXNIP inhibiting medication as a first-of-its-kind oral therapeutic for Type 1 and Type 2 diabetes. TIXiMED is the exclusive license holder for the patent (composition of matter and method of use) surrounding TIX100, a novel small molecule that normalizes pancreatic beta cell TXNIP, a detrimental protein elevated in Type 1 and Type 2 diabetes. Increased TXNIP causes pancreatic islet dysfunction and death of insulin-producing beta cells and thereby contributes to the development and progression of diabetes. Diabetes affects more than half a billion people worldwide. Those affected by Type 1 diabetes are dependent on multiple daily insulin injections or continuous insulin infusions to stay alive and manage their blood sugar. Oral anti-diabetic drugs are only approved for Type 2 diabetes, but can be associated with multiple side effects, underlining the need for novel and better oral diabetes medications for Type 1 and Type 2 diabetes. TXNIP inhibition has recently been demonstrated to be an effective and safe therapeutic approach in adults and children with recent onset Type 1 diabetes and TIX100 shows beneficial, anti-diabetic effects in 4 different mouse models. Advantages of TIX100 include oral availability, no associated hypoglycemia or weight gain, potent inhibition of detrimental TXNIP in human islets, and a favorable pharmacokinetic and safety profile. In addition, TIX100 inhibits excessive glucagon secretion and hepatic glucose production and protects against fatty liver. Thus, TIX100 holds promise for durable, weight-neutral improvement in glycemic control in Type 1 and Type 2 diabetes by targeting common underlying pathology and promoting patients’ own islet cell health.
Company Details
- Employees
- 3
- Founded
- -
- Address
- 1927 First Avenue North, Birmingham,al 35203,united States
- Industry
- Biotechnology Research
- Website
- https://tiximed.com/
- Keywords
- diabetes.
- HQ
- Birmingham, AL
Tiximed Questions
TIXiMED's website is https://tiximed.com/
TIXiMED's LinkedIn profile is https://www.linkedin.com/company/tiximed
TIXiMED has
3 employees.
View email and phone details for 3
employees at TIXiMED.
TIXiMED's industry is
Biotechnology Research
TIXiMED's top competitors are
Kitalys Institute,
Abvance Therapeutics,
The Helmsley Charitable Trust,
Hart's Mobility Llc,
Cmc-Rx Consultancy,
Closing The Gaps,
Eli Lilly And Company,
Rtmbio,
Kinexum Services Llc,
Theracosbio.
TIXiMED's categories are Biotechnology Research
TIXiMED's founding year is 2021
Top TIXiMED Employees
-
Jo Van Betsbrugge, PhD
President Cmc-Rx Consultancy | Cmc Drug Development Leader - Small Molecules & Peptides
Greater Montreal Metropolitan Area, Canada1bioquadrant.com -
Stephen Daly
Ceo, Tiximed
Henderson, Nevada, United States, United States -
Anath Shalev
Chief Scientific Officer At Tiximed
Birmingham, Alabama, United States, United States
Free Chrome Extension
Find emails, phones & company data instantly
Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Aero Online
Your AI prospecting assistant
Select data to include:
Total price:
$0.00
0 records × $0.02 per record
How It Works
Get a Free Account
Sign up for a free account. No credit card required. Up to 10 free credits.
Search the #1 Contact Database
Get contact details of over 750M+ profiles across 60M companies – all with industry-leading accuracy. Sales Navigator and Recruiter users, try out our Email Finder Extension.
Use our AI-Powered Email Finder
Find business and personal emails and mobile phone numbers with exclusive coverage across niche job titles, industries, and more for unparalleled targeting. Also available via our Contact Data API.